Next Generation Cancer Therapeutics

Next Generation Cancer Therapeutics is organized by Springer Nature and will be held from Oct 06 - 08, 2026 at The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

Description:
This conference will bring together leading researchers from academia, biotechnology and the pharmaceutical industry to discuss emerging strategies that are transforming the landscape of cancer therapeutics. We will highlight advances in the development of next-generation treatment modalities and the technologies that are enabling them.

Talks will cover next-generation biologics and immunotherapies, such as T-cell engagers, cancer vaccines, in vivo CAR approaches, oncolytic virotherapy and microbiome-based therapies. We will also explore new paradigms in targeted protein modulation, including molecular glues, PROTACs and RNA degraders, as well as emerging targeted therapies for historically challenging oncogenic drivers such as RAS.

In addition, we will address innovative therapeutic platforms and engineering approaches, including nanotechnology-based therapeutics, engineered bacteria and next-generation tumour models.

Conference sessions will focus on the following themes:

• Next-generation biologics
• Next-generation immunotherapy
• Next-generation targeted therapies
• Next-generation therapeutic platforms
• Artificial intelligence in therapeutics

Finally, we will examine how artificial intelligence is accelerating therapeutic development through AI-assisted drug design and screening, biomarker-guided therapy identification and patient stratification, agentic AI systems and foundation models.Starting on the morning of Tuesday October 6 and concluding in the early afternoon of Thursday October 8, the conference will include talks from approximately 23 invited speakers, short talks selected from submitted abstracts and poster sessions. This event will be led by presentations from the following keynote speakers:

• Christina Curtis- RZ Cao Professor of Medicine, Genetics & Biomedical Data Science, Stanford University (California, USA)y (California, USA)
• Paul Workman- Harrap Professor of Pharmacology and Therapeutics, The Institute of Cancer Research (London, United Kingdom)